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AbSTrACT
Culture- independent microbial sequencing techniques 
have revealed that the respiratory tract harbours a 
complex microbiome not detectable by conventional 
culturing methods. The contribution of the microbiome 
to chronic obstructive pulmonary disease (COPD) 
pathobiology and the potential for microbiome- based 
clinical biomarkers in COPD are still in the early phases 
of investigation. Sputum is an easily obtainable sample 
and has provided a wealth of information on COPD 
pathobiology, and thus has been a preferred sample 
type for microbiome studies. Although the sputum 
microbiome likely reflects the respiratory microbiome 
only in part, there is increasing evidence that microbial 
community structure and diversity are associated with 
disease severity and clinical outcomes, both in stable 
COPD and during the exacerbations. Current evidence 
has been limited to mainly cross- sectional studies using 
16S rRNA gene sequencing, attempting to answer 
the question ’who is there?’ Longitudinal studies 
using standardised protocols are needed to answer 
outstanding questions including differences between 
sputum sampling techniques. Further, with advancing 
technologies, microbiome studies are shifting beyond 
the examination of the 16S rRNA gene, to include whole 
metagenome and metatranscriptome sequencing, as 
well as metabolome characterisation. Despite being 
technically more challenging, whole- genome profiling 
and metabolomics can address the questions ’what 
can they do?’ and ’what are they doing?’ This review 
provides an overview of the basic principles of high- 
throughput microbiome sequencing techniques, current 
literature on sputum microbiome profiling in COPD, and 
a discussion of the associated limitations and future 
perspectives.
InTroduCTIon
Chronic obstructive pulmonary disease (COPD) is a 
highly prevalent respiratory disease and the leading 
cause of morbidity and mortality worldwide.1 2 It 
is heterogeneous, but many patients experience 
progressive airflow obstruction, exacerbations and/
or persistent symptoms of dyspnoea, cough and 
sputum production.2 Exacerbations are heteroge-
neous and vaguely defined as acute worsening of 
respiratory symptoms outside of normal day- to- day 
variation, usually associated with a healthcare utili-
sation event (eg, prescription of oral steroids and/or 
antibiotics, emergency room visit). They are associ-
ated with accelerated disease progression, increased 
mortality and major healthcare costs.2–4 The 
heterogeneity of COPD overall, and exacerbations, 
in particular, complicates the clinical assessment 
of disease severity and outcome. Determining the 
fundamental biology underlying COPD heteroge-
neity is vitally important, as is the identification of 
biomarkers to guide personalisation of therapeutic 
strategies.5–7
Elucidating the role of respiratory microbiota with 
respect to COPD pathobiology has potential impli-
cations for improving diagnostics and predicting 
outcomes.8–12 The respiratory microbiome, which 
may be assayed using culture- independent microbial 
sequencing, is characterised by the micro- organisms 
and their genomes present in the respiratory tract 
under specific environmental conditions (eg, expo-
sures or disease states).13 Metrics assessing respi-
ratory microbiome composition differ between 
healthy controls and COPD, and alterations in 
bacterial abundance and microbial diversity (ie, 
microbes present in differing proportions) correlate 
with altered airway inflammatory processes.14–17 
Current knowledge of the respiratory microbiome 
still relies mainly on the 16S rRNA gene sequencing 
approach. Other high- throughput techniques, 
such as metagenomics, metatranscriptomics and 
metabolomics, will aid in both a broader investi-
gation of microbial genomes and the examination 
of associated functional aspects. In this review, we 
provide an overview of the basic principles of high- 
throughput techniques for microbiome assessment 
and analytical approaches. Further, we discuss the 
current evidence, limitations and future perspec-
tives of sputum microbiome profiling in COPD.
basic principles of high-throughput sequencing 
techniques: 16S rrnA gene sequencing, 
shotgun metagenomics, metatranscriptomics, 
metabolomics
Culture- independent high- throughput sequencing 
techniques have revealed that the human body 
harbours a microbiome with a complexity far 
beyond the scope that is detectable by conven-
tional culturing methods.18 19 Importantly, cultiva-
tion efforts can be extended in order to increase 
the detection rate of microbes, which represents a 
significant benchmark for evaluating new culture- 
independent sequencing technologies.20 The choice 
of technique for microbiome assessment and 
characterisation should be based on the research 
question, with consideration of the strengths and 
weaknesses of each technique. The respiratory tract, 
certainly in stable COPD, is a low- biomass environ-
ment in which the microbial density decreases in 
a gradient from the upper (URT) to lower respira-
tory tract (LRT), where microaspiration from the 
URT is considered to be the dominant source.21 
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Therefore, microbial signals must be discerned from possible 
contamination during the sample collection and processing prior 
to analysis.22 23 Furthermore, appropriate sample collection 
and processing following standardised protocols, with partic-
ular attention to DNA and RNA extraction methods, should be 
followed as multiple steps in this process can influence microbe 
yield and diversity.24 A comprehensive discussion of best prac-
tices for microbiome analysis overall and with respect to the 
respiratory tract have been well described previously.22 23 25 26
16S rRNA gene sequencing was used in the pioneering work 
in respiratory microbiome research, and current knowledge still 
relies mainly on this approach.8 27 16S rRNA sequencing is based 
on PCR amplification using primers that target the 16S ribo-
somal gene variable regions of bacterial genomes, which can be 
used for taxonomic classification.28 This approach is rapid, well 
tested and relatively low cost. By focusing on a specific region of 
the bacterial genome, it requires only a limited sequencing depth. 
16 s rRNA sequencing is used to survey microbial communities, 
answering the question ‘who is there?’
There are many techniques for analysing microbial commu-
nities present within and across samples, but alpha and beta 
diversity are two of the most common metrics. Alpha diversity 
captures the number of operational taxonomic units (OTUs) 
present in a sample (‘richness’) and how they are distributed 
(‘evenness’), reducing the complexity of these relationships 
into a single metric. Commonly used alpha diversity metrics 
include the Shannon index or Simpson index.26 29 Beta diver-
sity compares the dissimilarity between samples and provides a 
matrix of distance. Alpha and beta diversity do not, however, 
capture the full complexity and dimensionality of microbial 
community relationships. Thus, more recent work has begun to 
explore the microbiome in the context of microbial community 
ecology.30 Community ecology theory provides a framework 
and set of analytical tools to consider how microbes interact 
with each other and their human host over time and space and 
in response to exposures or insults (eg, disease states). Newer 
sequencing approaches that capture microbial function and pres-
ence are poised to contribute greatly to our understanding of 
these ecological dynamics.
16S rRNA gene sequencing exhibits other important short-
comings that may be overcome by newer technologies. For 
example, it cannot distinguish between live and dead microbes, 
which may be relevant for several reasons, such as assessing 
the impact of antibiotic therapy in clinical samples.31 Also, 16S 
rRNA gene sequences are relatively short. Thus, closely related 
bacteria may share similar sequences, making a separation 
between different species challenging.26 Finally, 16S sequencing 
analyses are restricted to the detection of bacteria and archaea 
since viruses or fungi do not carry 16S rRNA genes.
Shotgun metagenomic sequencing is based on unrestricted 
DNA sequencing of genetic content in a sample. This approach 
can capture DNA- based viruses and eukaryotic DNA, including 
fungal microorganisms, in addition to bacteria.26 Shotgun metag-
enomics allows for an unbiased and deeper taxonomical analysis 
of the microbiome than 16S rRNA gene method, since dissim-
ilar regions of microbial genomes are sequenced. The assembly 
of short sequencing reads into larger fragments can increase the 
discriminatory power between microbes, enhancing taxonomic 
resolution up to the species or strain level.25 32 Feigelman et al 
demonstrated how unbiased DNA sequencing in sputum from 
patients with cystic fibrosis (CF) can enhance in- depth micro-
biome profiling.33 Furthermore, shotgun metagenomic analyses 
add insight into the question ‘what can these microbes do?’ The 
potential metabolic capacity of the microbiome can be evaluated 
by assigning microbial genes to pathway profiles and investi-
gating potential cross- talk between the microbiome and human 
host and between microbes.34 35
Metagenomic sequencing has several weaknesses. As with 
16S rRNA gene sequencing, it is unable to distinguish between 
live and dead microbes. The high sequencing depths necessary 
for taxonomic classification may be prohibitively expensive, 
although these costs are diminishing.25 26 Most respiratory 
viruses are RNA- based and therefore not detectable by metage-
nomic approaches. Additionally, pathway profiling of microbial 
genes will only allow for the evaluation of potential metabolic 
capacities, and can thus only conjecture at functional roles.
Metatranscriptomic sequencing examines RNA- level genetic 
content. RNA sequencing (RNA- seq) provides a survey of micro-
biota that include RNA- based respiratory viruses.36–38 Unlike 
DNA- based methods, metatranscriptomics focuses on living 
microbiota. By assessing gene expression (transcriptome) of the 
microbiota, it can enable a better assessment of microbial func-
tional activity. Further, this approach allows for a simultaneous 
assessment of the host transcriptome. Thus, metatranscrip-
tomics may provide broader insight into the question ‘what are 
they doing?’ than metagenomics by allowing for an assessment 
of functional interactions between different microbiota and 
between host and microbes.
There are drawbacks to metatranscriptomics as well.39 RNA is 
vulnerable with a short half- life and requires careful collection 
and storage associated with high costs. Further, results can be 
biased towards microbial genes with higher transcription rates. 
Consequently, it is preferable that RNA- based approaches are 
complemented by DNA- based sequencing so that RNA/DNA 
ratios and microbial transcriptional activity may be examined. 
Finally, the application of RNA- seq to microbiome research is 
still relatively new, especially with respect to the respiratory 
tract. Therefore, best practices for sample processing and anal-
ysis are still evolving.
Metabolomic data generation is based on chromatography 
techniques and detection methods, such as mass spectrometry 
or nuclear magnetic resonance, instead of sequencing.40 Appli-
cation of these technologies to microbiome research is still in its 
infancy and has been better studied in the gut than the respiratory 
tract. However, the techniques provide an opportunity to more 
accurately answer the question ‘what are the microbes doing?’ 
when used in combination with microbial and host sequencing 
that identify relevant alterations in microbial communities and 
host response. Microbial- derived metabolites include those 
synthesised directly by microbes and those produced by the host 
and biochemically modified by microbes.41 They are known to 
affect host physiology (host–microbiota interactions) as well 
as dynamics within the microbiome (microbe–microbe interac-
tions). They have been shown to play important roles in health 
and disease. These include crucial roles in the maintenance of 
the epithelium and immune cell function, processes dysregulated 
in COPD pathogenesis.41 42 Thus, metabolomics- based analyses 
provide a promising opportunity for studying microbial- host 
dynamics within the respiratory tract.
Overall, evolving high- throughput methods are revolution-
ising microbiome research. Although 16S rRNA gene sequencing 
is still the most common technology used in respiratory micro-
biome research, shotgun metagenomics, metatranscriptomics 
and metabolomics are increasingly applied to microbiome 
research in other compartments (eg, gastrointestinal tract). A 
crucial challenge remains the depletion of host DNA, which 
represents the vast majority of DNA present in low- biomass 
samples.22 Samples can be pretreated to reduce the host genome 
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background, however, its effect on an unbiased microbiome 
detection remains unknown.22 43 Further, standardisation of 
methods, including sample collection, processing and analytical 
pipelines, is required in order to further elucidate their utility in 
respiratory microbiome research.
Sputum microbiome profiling in CoPd: the current body of 
evidence
The respiratory tract is an anatomically and physiologically 
complex organ. Physiological parameters, such as pH level, rela-
tive humidity or temperature, change along the respiratory tract, 
creating niche- specific growth conditions for microbes.44 Conse-
quently, it is likely that the microbiome varies along the respi-
ratory tract. Furthermore, airway microbiome profiles depend 
on sampling method (eg, nasal brushing, induced or expecto-
rate sputum, bronchoalveolar lavage (BAL), epithelial brushing, 
bronchial biopsies) consistent with this niche specificity.17 45–47 
To exploit respiratory microbiome characteristics for COPD 
diagnostics, phenotyping and outcome prediction, it is neces-
sary to identify microbiome biomarkers that are easily obtain-
able in a patient- friendly manner. Sputum closely aligns with 
these characteristics, making it a preferred sampling technique. 
Sputum microbiome characteristics, such as microbial diversity 
or relative abundance, are associated with disease severity and 
outcomes in stable COPD and exacerbations (see online supple-
mentary table 1).10 11 45 48 49
Sputum microbiome profiles in stable COPD
In stable COPD, reduced sputum bacterial microbiome diversity 
has been shown to be associated with more severe airflow obstruc-
tion.17 45 49 50 Galiana et al found that participants with severe 
airflow obstruction exhibited lower alpha diversity and a higher 
bacterial load in sputum samples, compared with participants 
with mild or moderate airflow obstruction.49 This finding has 
since been reproduced in both sputum and BAL sampling.17 50 51 
These studies also reported a shift in the microbial flora with 
decreasing lung function towards potentially pathogenic bacte-
rial genera, particularly those belonging to the gammaproteo-
bacteria class (eg, Pseudomonas or Haemophilus spp). Thus, the 
observed decrease in microbial diversity appears to be associated 
with their outgrowth. Although reduced microbial diversity has 
been identified at other mucosal sites (eg, gastrointestinal tract) 
in association with chronic inflammatory diseases (eg, inflam-
matory bowel disease), it remains of interest whether these asso-
ciations are influenced by therapeutic interventions.52 Further, 
identifying causal relationships between chronic inflammation 
and microbial community changes is an active area of research.
The association between bacterial load and features of stable 
COPD appears to be complex and affected by chosen thera-
pies.49 53 Garcha et al showed that higher bacterial load of poten-
tial pathogens, such as Haemophilus influenzae, Streptococcus 
pneumoniae, Moraxella catarrhalis, correlated with more severe 
airflow limitation in stable COPD.53 Further, they reported a 
positive correlation between bacterial load and inhaled corti-
costeroids (ICS) dosage. In a randomised controlled trial, Brill 
et al reported that chronic antibiotic therapy, often used as an 
exacerbation preventative therapy, was associated with a ≥3 fold 
increase in antibiotic resistance among airway bacteria without 
decreasing the total bacterial load in sputum.54 These associa-
tions between therapies and microbial load or function suggest 
that therapies regularly used in COPD management may have 
unintended consequences on the microbiome, although the 
significance of these consequences is unclear.
There is preliminary evidence that sputum microbial commu-
nities from COPD patients with more severe airflow obstruc-
tion may have shifted such that they lack potentially commensal 
bacteria, favouring more pathogenic microbes.49 Several studies 
identified potential commensal bacteria in the URT, including 
Dolosigranulum spp and Corynebacterium spp, which appear to 
be associated with respiratory health and pathogen clearance.55–57 
Galiana et al found that the potentially commensal bacterial 
genus Actinomyces was less frequently recovered in sputum 
from patients with COPD with severe compared with moderate 
airflow obstruction.49 Iwase et al showed that commensal respi-
ratory bacteria can directly suppress the outgrowth of potential 
pathogens belonging to the same genus or family, highlighting 
the importance of microbe–microbe interactions in maintaining 
homeostasis.58 Potential new therapeutic approaches might not 
only aim at reducing colonisation of pathogenic microbes but 
also at increasing colonisation of commensal bacteria in the 
respiratory tract.
Sputum microbiome profiles in COPD exacerbations
GOLD guidelines recommend performing sputum cultures in 
patients with frequent exacerbations, severe airflow limitation 
and/or those requiring mechanical ventilation.2 While the goal 
of sputum culture in this setting is to determine the presence of 
bacterial pathogens and to guide antibiotic treatment, culture is 
very limited in this role.59–61
Evaluating the sputum microbiome with modern high- 
throughput sequencing technologies might contribute to 
enhanced exacerbation precipitant diagnosis. Sputum micro-
biome profiles have been shown to exhibit dynamic changes 
between stable COPD and exacerbations in at least a patient 
subset, involving the outgrowth of pathogens, decreased micro-
bial diversity and increased abundance of pathogenic bacterial 
communities.11 62 There is also evidence that bacterial outgrowth, 
as occurs in overt infection, may not be necessary for bacteria to 
trigger an exacerbation. Strain shifts towards more pathogenic 
bacterial strains, without an overall change in bacterial abun-
dance, have been identified as potential precipitants for some 
exacerbations.63
Host biomarkers and microbial profiling in sputum samples 
suggest that at least three exacerbation subtypes exist, defined 
by both the airway inflammatory state and the suspected exacer-
bation precipitant: bacterial, viral and eosinophilic.10 Ghebre et 
al found that sputum samples clustered by exacerbation subtype 
exhibited differing microbial community characteristics.10 Exac-
erbations categorised as bacteria associated had the greatest 
Proteobacteria abundance and a high Proteobacteria/Firmicutes 
ratio in their sputum, while exacerbations categorised as eosin-
ophilic exhibited greater sputum microbial alpha diversity.10 
Mayhew et al found that exacerbations classified as bacterial 
and eosinophilic were more like to be repeated within a subject 
over time than viral exacerbations.51 Thus, exacerbations exhibit 
substantial biological heterogeneity. Considering exacerbations 
within the subtyping framework may add considerably to our 
understanding of underlying mechanisms and provide insight 
into more appropriate precision- guided management.
Although changes in bacterial community structure appear to 
occur in only an exacerbation subset, dysbiosis is indeed associ-
ated with particular exacerbation features and worse outcomes. 
Wang et al found that the sputum microbial community compo-
sition changes significantly from stable to exacerbation state in 
only ~40% of their cohort.48 Participants with microbial dysbi-
osis had worse health status and lung function, particularly if 
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they also had evidence of eosinophilic inflammation. Further-
more, the abundance of Moraxella spp increased in this study, 
corroborating other reports that find specific pathogenic phyla 
and genera are enriched in the exacerbation microbiome.11 62 
Leitao Filho et al found that reduced sputum microbial alpha 
diversity and altered beta diversity during hospitalised exac-
erbations were associated with increased 1- year mortality.64 
Interestingly, associations between limited diversity and disease 
progression has also been described in other lung diseases, such 
as CF.65 Together, these results indicate that the heterogeneous 
contribution of microbes to exacerbations may be clinically 
relevant.
Several reports have speculated that the contribution of typi-
cally non- pathogenic bacteria to alterations in microbial commu-
nity ecology may be crucial to exacerbation pathogenesis. Wang 
et al identified an outgrowth of non- pathogenic Proteobacteria, 
in addition to pathogenic microbiota, during exacerbations. They 
speculate that this state of dysbiosis, with differing microbe–
microbe and microbe–host interactions, leads to a dysregulated 
host inflammatory response.11 66 Huang et al reported a positive 
relationship between the abundance of COPD- associated patho-
gens during an exacerbation, (eg, H. influenzae, Pseudomonas 
aeruginosa or Moraxella catarrhalis) and phylogenetically related 
non- pathogenic bacteria.62 Leitao Filho et al speculate that the 
absence of potentially commensal bacterial genera in the sputum 
microbiome is associated with clinical outcomes in exacerba-
tions.64 They found that both the presence of Staphylococcus 
spp (potentially pathogenic) and the absence of Veillonella spp 
(potentially commensal) in sputum were strongly associated with 
the increased risk of mortality after 1 year. This work highlights 
the need for a better understanding of the role of both patho-
genic and commensal microbes within the respiratory micro-
biome during exacerbations.
Importantly, two studies did not find changes in diversity 
metrics between disease stability and exacerbations.51 67 Millares 
et al additionally failed to identify changes in bacterial abun-
dance but did report changes in functional metabolic pathways 
of the microbiome during exacerbations. Mayhew et al did not 
identify a change in diversity metrics but did find an increase 
in the relative abundance of Moraxella spp during exacerba-
tions.51 67 These reports provide further evidence of the overall 
phenotypic heterogeneity in exacerbations, but also emphasise 
the potential importance of strain shifts without changes in 
species or class- level microbial community structure in precip-
itating bacterial exacerbations.
Standardised follow- up studies are required to validate current 
findings. Eventually, causation and mechanisms between sputum 
microbial community structure and host inflammatory response 
require further investigation, which demands causal models 
and rigorous methods.68 69 A promising approach was recently 
published by Sanna et al, using a bidirectional Mendelian rando-
misation analysis to assess causality between the gut microbiome 
and metabolic diseases.70
Sputum microbiome profiles after therapeutic interventions of 
exacerbations
Current knowledge about the impact of empirical approaches to 
the treatment of exacerbations on sputum microbiome profiles is 
still scarce. Wang et al reported that steroid treatment alone was 
associated with reduced alpha diversity, increased abundance of 
Proteobacteria (including Haemophilus and Moraxella spp) and 
an increased Proteobacteria:Firmicutes ratio, whereas opposite 
trends were found in exacerbations treated with antibiotics (with 
or without steroids).11 Huang et al also reported an enrichment 
of Proteobacteria, in addition to other bacterial phyla with 
steroid treatment, indicating that this treatment alone might 
increase the burden of specific microbiota.62 In the same study, 
antibiotic treatment had suppressive effects on this bacterial 
burden. In contrast to Wang et al findings, Huang et al observed 
a trend towards increased microbial diversity after steroid treat-
ment and decreased diversity following antibiotic treatment.
Further research is needed to better understand treatment 
effects on respiratory microbial dynamics over time as well 
as microbial–host interactions. Segal et al took a promising 
approach to study the antimicrobial effects of azithromycin in 
COPD.71 Using a combination of 16S sequencing and metab-
olomics they found decreased alpha diversity in azithromycin- 
treated BAL samples and increased bacteria- produced metabolites 
known to influence the host inflammatory response. More mult-
‘omic studies integrating microbial and host data are needed to 
elucidate and characterise the potentially deleterious impact of 
chronic therapies in COPD to better guide therapy decisions.
In summary, the current body of evidence indicates that the 
severity of COPD is inversely correlated with sputum micro-
bial diversity and is associated with an outgrowth of poten-
tially pathogenic bacteria. Exacerbation subtypes exhibit altered 
sputum microbial community characteristics, providing poten-
tial targets for precision- guided management. Further studies, 
integrating microbial and host information, are needed to under-
stand the impact of therapeutic interventions on the microbiome 
and interactions with the host. Eventually, potential new ther-
apeutic approaches might not only aim at reducing the colo-
nisation of pathogenic microbes but also to either increase the 
colonisation of commensal bacteria or modulate the associated 
host response.
Sputum microbiome profiling in CoPd: limitations, challenges 
and future perspectives
There are several limitations of sputum microbiome profiling as 
well as challenges that should be addressed in future studies to 
better assess the utility of the technique in COPD microbiome 
research (figure 1): 
Limitations and challenges: the biogeography of sputum
LRT sampling methods, such as BAL and bronchial biopsies or 
brushings, are invasive approaches and thus poorly suited for 
longitudinal assessment. However, COPD is generally a disease 
of the LRT. Thus, understanding the similarities and differences 
between these LRT sampling methods and more easily obtain-
able sputum sampling is essential for interpretation.47 72 In a 
small study (n=20), Sulaiman et al found that induced sputum 
microbiota were more similar to those obtained by oral wash 
than those obtained from the lower airway (bronchial biopsies) 
in participants with and without non- tuberculous mycobacterial 
infections.72 Durack et al also reported an enrichment of oral 
bacteria in induced sputum samples compared with bronchial 
biopsies.47 However, they found that the abundance of genera 
identified in bronchial biopsies correlated quite well with those 
detected in both induced sputum and oral wash. Thus, despite 
the overall difference in microbial composition between URT 
and LRT sampling, sputum does have utility in assessing LRT 
microbiome composition, in particular, relative microbial abun-
dance. These correlations between lower and upper airway 
microbe abundance underscore the theory that microaspiration 
of microbes from the URT is the primary source of bronchial 
microbiota.21 46 73 While characterising the airway microbiome 
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Figure 1 Sputum microbiome profiling—beyond singular pathogen detection. COPD, chronic obstructive pulmonary disease.
using sputum should be done considering the limitations, the 
considerable strengths in comparison to LRT sampling should be 
considered as well. Sputum is easily obtainable and alterations in 
the sputum microbiome correlate with clinical outcomes. Thus, 
sputum microbiome biomarkers may be useful even if they do 
not accurately reflect the LRT microbiome.
Limitations and challenges: induced versus spontaneously 
expectorated sputum
Differences in microbiome profiles obtained from spontaneous 
versus induced sputum samples are particularly understudied. 
Although patients without spontaneous sputum production can 
safely undergo sputum induction even during exacerbations, 
preliminary results suggest that microbial composition may be 
affected by sampling technique.74–76 Furthermore, Gershman et 
al found that the duration of sputum induction affects the host 
cellular and biochemical composition in samples and suggest 
that the large airways are sampled at the beginning, whereas 
peripheral airways are sampled at later time periods.77 Tangedal 
et al found that microbiota compositions differed between pair-
wise spontaneous and induced sputum samples in participants 
with COPD.76 Further studies are needed in which protocols, 
and in particular sputum volume obtained, sample quality and 
procedure duration, are standardised across expectorated and 
induced sputum sampling.
Limitations and challenges: reproducibility of findings
COPD sputum microbiome studies to date have mainly used a 
cross- sectional design. Within- individual longitudinal microbial 
profiling reports are lagging, but data are starting to emerge. 
Sinha et al collected repeated induced sputum samples from 
four stable patients ith COPD over 9 months. They reported 
the stability of bacterial composition and diversity over 2 days, 
with increased variability over 9 months.78 In a larger longitu-
dinal cohort (n=101), Mayhew et al found relative stability in 
microbial composition in a participant subset,51 while those with 
more variability were more likely to have higher exacerbation 
frequency.
Overall, both within- individual and between- cohort repro-
ducibility represent crucial milestones in the development of a 
biomarker and require further scientific attention and evaluation 
with respect to sputum microbiome profiles in COPD.79 80
Future perspectives: integrate the non-bacterial microbiome
16S rRNA sequencing approaches in sputum samples have provided 
important insights into the dynamics of the bacterial microbiome 
in stable COPD and exacerbations. However, the respiratory 
microbiome includes viruses and fungi as well as bacteria. The 
prevalence and clinical significance of fungi (mycobiome) in the 
respiratory tract in the context of COPD are particularly under-
studied.81 82 Bacterial- fungal and bacterial- viral interactions can 
affect microbial dynamics and microbe–host interactions and 
require further attention.83 84 Furthermore, the outgrowth of 
potentially pathogenic bacteria can be influenced by prior non- 
bacterial infections. Postviral bacterial respiratory infections are 
common overall. However, Molyneaux et al suggest that postviral 
bacterial dysbiosis is particularly an issue in COPD. They found 
that rhinovirus infection was followed by an outgrowth of H. influ-
enzae in COPD sputum samples and associated with an increased 
neutrophilic inflammatory response.85 They did not observe this 
outgrowth in healthy controls.
Overall, mechanisms of postviral secondary bacterial infec-
tions are known to be complex, mediated by interactions between 
viruses and bacteria (intermicrobial interactions) as well as the 
host immune system.86 It will be crucial to evaluate not only 
bacterial microbiome dynamics but viral and fungal dynamics as 
well, to evaluate the influence of inter- microbial interactions on 
both homoeostasis and pathogenesis within the respiratory tract. 
Shotgun metatranscriptomic approaches may be particularly well 
suited to these types of analyses as they can survey both bacte-
rial and non- bacterial microbes and may provide an assessment of 
functional activity.
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Future perspectives: integrate the host response
Although technically challenging, high- throughput sequencing 
techniques, such as metatranscriptomics, offer the possibility 
to simultaneously sequence the host and microbial genomes.36 
In principle, host genome and microbiome profiles could be 
analysed in ‘one run’ in airway samples from COPD patients, 
offering the possibility to directly analyse the interactions 
between microbiota and the host immune profiles on a personal 
genome level. Langelier et al recently demonstrated how the 
integration of host response and microbiome profiling can 
contribute to diagnosis and characterisation of LRT infections 
(LRTI) in critically ill patients with acute respiratory failure, 
based on metagenomic and metatranscriptomic sequencing in 
tracheal aspirate samples.87 Combining pathogen, microbiome 
and host gene expression metrics enhanced LRTI diagnosis in 
cases of unknown aetiology, showcasing the potential of this 
model to optimise diagnostics for airway diseases.
ConCLuSIon
In conclusion, high- throughput sequencing techniques allow 
for an increasingly detailed assessment of the COPD airway 
microbiome. Sputum likely only partially represents the respi-
ratory microbiome in COPD, given the enrichment for oral 
flora. However, the increasing evidence of sputum microbiome 
associations with characteristics of stable COPD and exacerba-
tions, treatment response, and outcomes suggest that sputum 
microbiome profiling may provide important biomarkers to 
better understand COPD biology and guide therapies. Many 
outstanding questions remain. Answering these questions will 
take exacting studies implementing standardised protocols and 
employing the evolving technologies and statistical approaches 
to study microbial community structure in relation to the COPD- 
relevant host response.
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